GlassScriptPhysician profile
Albert Joseph Rudick
NPI 1457400913
$1,902.68
in general payments reported to CMS, 2019-2025
15 companies · $597 in 2025
The $597 reported for 2025 was more than what a typical Cornea and External Diseases Specialist provider received nationally (typical 2025 total: $477).
See the full distribution for Cornea and External Diseases Specialist
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $223 · 2020: $130 · 2021: $387 · 2022: $246 · 2023: $61.35 · 2024: $258 · 2025: $597.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $917.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $916.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $347.45 | 2024-2025 | Xdemvy |
| Allergan, INC. | $264.28 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $195.22 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $182.86 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Sun Pharmaceutical Industries INC. | $177.52 | 2019-2025 | |
| Alcon Vision LLC | $154.28 | 2022-2025 | Tryptyr, Eysuvis, Rocklatan |
| Harrow Eye, LLC | $147.76 | 2025 | Vevye |
| Lumenis Be INC | $136.22 | 2022 | |
| Novartis Pharmaceuticals Corporation | $82.31 | 2019-2022 | |
| Kala Pharmaceuticals, INC. | $59.38 | 2021 | |
| Dompe US, INC. | $54.13 | 2025 | Oxervate |
| Shire North American Group INC | $48.28 | 2019 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Johnson & Johnson Vision Care, INC. | $18.33 | 2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $15.26 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albert Rudick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.